Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OCUL Stock Forecast 2026-2027
$11.07
Current Price
$2.36B
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OCUL Price Targets
+180.0%
To High Target of $31.00
+103.3%
To Median Target of $22.50
+71.6%
To Low Target of $19.00
OCUL Price Momentum
-2.7%
1 Week Change
-21.9%
1 Month Change
+36.2%
1 Year Change
-8.8%
Year-to-Date Change
-32.7%
From 52W High of $16.44
+91.4%
From 52W Low of $5.79
📊 TOP ANALYST CALLS
Did OCUL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ocular Therapeutix is one of their latest high-conviction picks.
Latest OCUL Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, OCUL has a bullish consensus with a median price target of $22.50 (ranging from $19.00 to $31.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $11.07, the median forecast implies a 103.3% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Biren Amin at Piper Sandler, projecting a 180.0% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 71.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OCUL Analyst Ratings
12
Buy
0
Hold
0
Sell
OCUL Price Target Range
Low
$19.00
Average
$22.50
High
$31.00
Current: $11.07
Latest OCUL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OCUL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $21.00 |
| Dec 8, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $21.00 |
| Dec 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $20.00 |
| Nov 25, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $19.00 |
| Nov 5, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $21.00 |
| Oct 30, 2025 | TD Cowen | Tara Bancroft | Buy | Maintains | $20.00 |
| Oct 8, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $19.00 |
| Oct 3, 2025 | Piper Sandler | Biren Amin | Overweight | Maintains | $31.00 |
| Oct 3, 2025 | Baird | Colleen Kusy | Outperform | Maintains | $24.00 |
| Oct 2, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $21.00 |
| Oct 1, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $29.00 |
| Oct 1, 2025 | Needham | Serge Belanger | Buy | Maintains | $20.00 |
| Sep 15, 2025 | Chardan Capital | Daniil Gataulin | Buy | Initiates | $21.00 |
| Aug 6, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $20.00 |
| Aug 5, 2025 | Needham | Serge Belanger | Buy | Maintains | $15.00 |
| May 29, 2025 | HC Wainwright& Co. | Buy | Reiterates | $N/A | |
| May 29, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $15.00 |
| May 6, 2025 | Needham | Serge Belanger | Buy | Maintains | $14.00 |
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $15.00 |
| Apr 8, 2025 | William Blair | Lachlan Brown | Outperform | Initiates | $N/A |
Ocular Therapeutix Inc. (OCUL) Competitors
The following stocks are similar to Ocular Therapeutix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
OCUL
Ocular Therapeutix
mkt cap
2.40B
Ocular Therapeutix Inc. (OCUL) Financial Data
Ocular Therapeutix Inc. has a market capitalization of $2.36B with a P/E ratio of -9.1x. The company generates $55.78M in trailing twelve-month revenue with a 91.2% profit margin.
Revenue growth is -5.7% quarter-over-quarter, while maintaining an operating margin of -472.3% and return on equity of -81.8%.
Valuation Metrics
Market Cap
$2.36B
Enterprise Value
$2.01B
P/E Ratio
-9.1x
PEG Ratio
-0.1x
Price/Sales
40.8x
Growth & Margins
Revenue Growth (YoY)
-5.7%
Gross Margin
+87.8%
Operating Margin
-472.3%
Net Margin
+91.2%
EPS Growth
-5.7%
Financial Health
Cash/Price Ratio
+14.6%
Current Ratio
7.9x
Debt/Equity
29.8x
ROE
-81.8%
ROA
-36.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ocular Therapeutix Inc. (OCUL) Business Model
About Ocular Therapeutix Inc.
What They Do
Develops innovative therapies for eye diseases.
Business Model
The company generates revenue through the development and commercialization of sustained-release ophthalmic therapies, utilizing its proprietary hydrogel technology. By addressing unmet medical needs in ophthalmology, it aims to improve patient outcomes and enhance compliance with treatments, particularly for conditions like post-surgical inflammation and dry eye disease.
Additional Information
With a strong pipeline of product candidates, including the FDA-approved DEXTENZA, Ocular Therapeutix is positioned as a key player in the ophthalmology sector. The company focuses on partnerships and innovation, contributing to advancements in eye care and demonstrating potential for significant clinical and commercial impact.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
274
CEO
Dr. Pravin U. Dugel M.D.
Country
United States
IPO Year
2014
Website
www.ocutx.comOcular Therapeutix Inc. (OCUL) Latest News & Analysis
Latest News
Quick Summary
Baird analysts indicate that the biotechnology sector's strong fundamentals and innovation may lead to continued outperformance this year, despite macroeconomic risks like rising interest rates.
Why It Matters
Strong fundamentals and innovation in biotechnology suggest potential growth, outweighing macroeconomic risks, which could lead to better returns for investors in this sector.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Ocular Therapeutix Inc. (NASDAQ: OCUL) stock rose after the company expedited its New Drug Application submission for Axpaxli (OTX-TKI) to treat wet age-related macular degeneration.
Why It Matters
Ocular Therapeutix's accelerated NDA submission for Axpaxli signals potential faster market entry, boosting investor confidence and stock value amid growing demand for wet AMD treatments.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Ocular Therapeutix granted inducement awards to eight new non-executive employees as part of its 2019 Inducement Stock Incentive Plan, complying with Nasdaq regulations.
Why It Matters
The grant of inducement awards indicates Ocular Therapeutix's commitment to attracting talent, potentially enhancing innovation and growth, which can positively impact future performance and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet
1 month ago
Quick Summary
Ocular Therapeutix (OCUL) has an 82.5% upside potential per consensus price target. Earnings estimate revisions suggest possible near-term stock gains.
Why It Matters
An 82.5% upside potential suggests significant growth for Ocular Therapeutix (OCUL), and positive earnings estimate revisions may indicate imminent stock price increases.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Ocular Therapeutix, Inc. (OCUL) held its Q3 2025 earnings call, providing updates on financial performance and business developments. Further details on results may be available in the transcript.
Why It Matters
Ocular Therapeutix's Q3 2025 earnings call provides insights into financial performance, growth potential, and product developments, which can influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
2 months ago
Quick Summary
AXPAXLI™ showcased at Investor Day for its potential to redefine retina treatment, emphasizing a superiority label, market expansion, and immediate adoptability for investors.
Why It Matters
AXPAXLI™'s potential superiority and market expansion could lead to increased sales and market share, enhancing revenue growth and investor returns in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About OCUL Stock
What is Ocular Therapeutix Inc.'s (OCUL) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Ocular Therapeutix Inc. (OCUL) has a median price target of $22.50. The highest price target is $31.00 and the lowest is $19.00.
Is OCUL stock a good investment in 2026?
According to current analyst ratings, OCUL has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OCUL stock?
Wall Street analysts predict OCUL stock could reach $22.50 in the next 12 months. This represents a 103.3% increase from the current price of $11.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ocular Therapeutix Inc.'s business model?
The company generates revenue through the development and commercialization of sustained-release ophthalmic therapies, utilizing its proprietary hydrogel technology. By addressing unmet medical needs in ophthalmology, it aims to improve patient outcomes and enhance compliance with treatments, particularly for conditions like post-surgical inflammation and dry eye disease.
What is the highest forecasted price for OCUL Ocular Therapeutix Inc.?
The highest price target for OCUL is $31.00 from Biren Amin at Piper Sandler, which represents a 180.0% increase from the current price of $11.07.
What is the lowest forecasted price for OCUL Ocular Therapeutix Inc.?
The lowest price target for OCUL is $19.00 from Yi Chen at HC Wainwright & Co., which represents a 71.6% increase from the current price of $11.07.
What is the overall OCUL consensus from analysts for Ocular Therapeutix Inc.?
The overall analyst consensus for OCUL is bullish. Out of 16 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $22.50.
How accurate are OCUL stock price projections?
Stock price projections, including those for Ocular Therapeutix Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:50 AM UTC